Flush with $85 million in cash from its May 2013 IPO, armed with an outstanding scientific hypothesis, staffed by a world expert on leukemia, and nearly through with phase 2 clinical trials, Ambit Biosciences (AMBI) seems to be on the fast track to success. At the end of May, the esteemed private equity firm Orbimed purchased almost 1.5 million shares. The stock has nearly doubled to $13.52 since the beginning of July. Citigroup has given the company a rating of Outperform. Yet despite these excellent optics, careful review of the science and the economics indicates that common shareholders will almost certainly lose money, and probably all of it.
AMBI data by YCharts
Ambit currently has four drugs in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|